MELVILLE, N.Y., Dec. 31, 2013 /PRNewswire/ -- Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today announced the completion of a 60% equity investment in BioHorizons, Inc., a U.S.-based manufacturer of advanced dental implant technology and tissue regeneration products sold globally. This transaction was first announced on November 26, 2013.
Together with the Company's investment in CAMLOG Biotechnologies AG, a leading manufacturer of dental implants in Europe, Henry Schein now has important positions in the U.S. and German implant markets, as well as a growing presence in the rest of the world. The investment in BioHorizons also strengthens Henry Schein's position and product portfolio in the biologics market, which is a critical adjunct to the implant market.
"With the completion of this strategic investment in BioHorizons we have advanced our dental specialties markets business strategy and now have a stronger presence in two of the world's largest markets for dental implants," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Implant dentistry is a critical element of the profession's transition to digital dentistry, and customer demand for implants and the associated materials is expected to increase as digital processes are adopted and the patient's dental experience is enhanced."
"On behalf of the shareholders and management of BioHorizons, we are delighted with the closing of the transaction and the partnership with Henry Schein which combines BioHorizons' impressive growth with Henry Schein's global strengths," said Mortimer Berkowitz III, Chairman of BioHorizons and President of HealthpointCapital, LLC. "We look forward to working with Henry Schein and the BioHorizons team to strengthen our presence in the growing implant dentistry market by continuing to develop differentiated products for our customers."
About BioHorizons BioHorizons is a leader in advanced dental implant technologies and tissue regeneration products in the dental implant industry. Based in Birmingham, Alabama, the company offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products and surgical planning software.
BioHorizons' unique dental implant designs are recognized for intuitive design, excellent primary stability and high-end, aesthetic outcomes through the use of its proprietary Laser-Lok® microchannel surface technology. With 25 years of research and 30 published studies, Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long-term tissue maintenance. The company has six international subsidiaries and more than 50 distributors around the world. For more information, visit the BioHorizons Web site www.biohorizons.com.
About HealthpointCapital, LLC. HealthpointCapital is a growth buyout private equity firm which is exclusively focused on the musculoskeletal sector. It was formed in 2002 and has $750 million in assets under management. It became a majority owner of BioHorizons through an acquisition of the Company in 2006. For more information, visit the HealthpointCapital Web site www.healthpointcapital.com
About Henry Schein, Inc. Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the NASDAQ 100® Index, Henry Schein employs nearly 16,000 Team Schein Members and serves nearly 800,000 customers.